137 related articles for article (PubMed ID: 15289870)
21. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.
Kawakami M; Staub J; Cliby W; Hartmann L; Smith DI; Shridhar V
Int J Oncol; 1999 Oct; 15(4):715-20. PubMed ID: 10493953
[TBL] [Abstract][Full Text] [Related]
22. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
[TBL] [Abstract][Full Text] [Related]
23. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
24. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
Nagasawa T; Zhang Q; Raghunath PN; Wong HY; El-Salem M; Szallasi A; Marzec M; Gimotty P; Rook AH; Vonderheid EC; Odum N; Wasik MA
Leuk Res; 2006 Mar; 30(3):303-12. PubMed ID: 16185764
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
[TBL] [Abstract][Full Text] [Related]
26. Expression of the p16INK4a gene and methylation pattern of CpG sites in the promoter region in rat tumor cell lines.
Honoki K; Tsujiuchi T; Mori T; Yoshitani K; Tsutsumi M; Takakura Y; Mii Y
Mol Carcinog; 2004 Jan; 39(1):10-4. PubMed ID: 14694443
[TBL] [Abstract][Full Text] [Related]
27. Methylation silencing of the Apaf-1 gene in acute leukemia.
Furukawa Y; Sutheesophon K; Wada T; Nishimura M; Saito Y; Ishii H; Furukawa Y
Mol Cancer Res; 2005 Jun; 3(6):325-34. PubMed ID: 15972851
[TBL] [Abstract][Full Text] [Related]
28. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
[TBL] [Abstract][Full Text] [Related]
30. Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells.
Ren JZ; Huo JR
Med Oncol; 2012 Jun; 29(2):915-8. PubMed ID: 21298366
[TBL] [Abstract][Full Text] [Related]
31. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
Ribeiro-Filho LA; Franks J; Sasaki M; Shiina H; Li LC; Nojima D; Arap S; Carroll P; Enokida H; Nakagawa M; Yonezawa S; Dahiya R
Mol Carcinog; 2002 Aug; 34(4):187-98. PubMed ID: 12203370
[TBL] [Abstract][Full Text] [Related]
32. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.
Doerr JR; Malone CS; Fike FM; Gordon MS; Soghomonian SV; Thomas RK; Tao Q; Murray PG; Diehl V; Teitell MA; Wall R
J Mol Biol; 2005 Jul; 350(4):631-40. PubMed ID: 15967459
[TBL] [Abstract][Full Text] [Related]
33. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
34. Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b.
Kwon O; Jeong SJ; Kim SO; He L; Lee HG; Jang KL; Osada H; Jung M; Kim BY; Ahn JS
Carcinogenesis; 2010 Jul; 31(7):1194-201. PubMed ID: 20375073
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
36. Promoter methylation of cyclin D2 gene in gastric carcinoma.
Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
[TBL] [Abstract][Full Text] [Related]
37. Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.
Sheng Y; Wang H; Liu D; Zhang C; Deng Y; Yang F; Zhang T; Zhang C
Gynecol Oncol; 2016 Jan; 140(1):145-51. PubMed ID: 26597461
[TBL] [Abstract][Full Text] [Related]
38. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
39. The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
Kimura K; Toyooka S; Tsukuda K; Yamamoto H; Suehisa H; Soh J; Otani H; Kubo T; Aoe K; Fujimoto N; Kishimoto T; Sano Y; Pass HI; Date H
Oncol Rep; 2008 Nov; 20(5):1265-8. PubMed ID: 18949431
[TBL] [Abstract][Full Text] [Related]
40. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
